In vivo experiments showed that m6A demethylation by ALKBH5 fine-tunes the activity of splicing factor encoded by SF3B1 and other epigenetic regulators, indicating that ALKBH5 may delay HSC leukemic transformation in patients with MDS [36]. Here, ALKBH5 is linked to myelodysplastic syndrome.